Usability Study of Targeted Vibration Therapy for Tremor Relief

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Subjects will receive prototype devices to be used for participation. The study comprises three phases: 1. Alpha phase: Two remote study visits and an in-home period to gather device usability data on the alpha system. The at home period for this phase will be 2 weeks. This phase will be used to confirm that the device and labeling are suitable for in-home use. 2. Beta Phase B1: Beta Phase B1 will be conducted using the beta devices for two in-person or remote, 60 to 90-minute, visits. This phase will be used to assess design changes between alpha and beta versions. 3. Beta Phase B2: Seven remote visits and in-home usage to gather usability and efficacy data on the beta system in-home. Beta Phase B2 will be conducted using the beta devices for 12 weeks. This phase will be used to assess design changes between alpha and beta versions.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18 years or older, able to comply with all study procedures and capable of providing informed consent.

• Mentally competent to understand and able to perform written, informed consent to participate in the study

• A diagnosis of either ET or PD as determined by clinical history

• Moderate to severe upper limb tremor

• Age 18 years or older, able to comply with all study procedures and capable of providing informed consent

• Mentally competent to understand and able to perform written, informed consent to participate in the study

• For ET subjects, a diagnosis of essential tremor defined as definite or probable ET based on TRIG criteria

• For PD subjects, a diagnosis of Parkinson's disease by a Movement Disorder Specialist

• For ET subjects, at least one hand exhibiting tremor \> 2 as assessed by the Essential Tremor Rating Assessment Scale (TETRAS) finger to nose task, duck wing task, OR Archimedes Spiral completed during the Screening visit

• For PD subjects, a score \> 2 on at least one of MDS-UPDRS items 3.15, 3.16 or 3.17 At the Screening Visit, a score of \> 3 on one of the following subject-assessed items of the Bain \& Findley Activities of Daily Living Scale (BF-ADL): Use a spoon to drink soup, Hold a cup of tea, Do up buttons, Do up a zipper, Write a letter

• Stable medications for at least 30 days prior to enrollment and the ability to maintain tremor medications throughout the duration of study participation

• For PD subjects, able to participate in visits in a practically defined OFF state (withdrawal from all tremor medication for 12 hours prior to study visits)

• A wrist circumference of 6.0 - 8.1 inches

Locations
United States
Massachusetts
Encora Therapeutics
RECRUITING
Cambridge
Contact Information
Primary
Allison Davanzo
alli@encoratherapeutics.com
855-937-5302
Time Frame
Start Date: 2025-01-01
Estimated Completion Date: 2026-06
Participants
Target number of participants: 80
Treatments
Experimental: A
Oder of assessment begins with TETRAS and ends with ADLs
Experimental: B
Order of assessment begins with ADLs and ends with TETRAs
Experimental: C
Order of assessment begins with TETRAS and ends with ADLs, but both are administered backwards
Experimental: D
Order of assessment begins with ADLs and ends with TETRAs, but both are administered backwards
Sponsors
Leads: Encora, Inc.

This content was sourced from clinicaltrials.gov